Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 03/23 09:00:07 pm
97.46 USD   -0.65%
03/23ABBVIE : Is The AbbVie Dip A Buying Opportunity?
03/22S&P 500 MOVERS : Abbv, cmg
03/22EXACT SCIENCES : lures leader of AbbVie's top-selling Humira sales t..
Analysis summary4-Traders Strategies

A likely recovery

share with twitter share with LinkedIn share with facebook
share via e-mail
02/13/2015 | 03:06pm

Technical indicators currently tested are likely to allow AbbVie shares to rally again.

The research-based biopharmaceutical company displays high-quality fundamentals. It has an attractive valuation with a P/E ratio of 13.3x for 2015 and an appealing yield of 3.43%. Reuters estimates shows its outstanding growth potential and its rising profitability: EPS should increase by 290% in 2015.

Technically, the stock is in an oversold situation. Prices came back on their lower ascendant trendline on both daily and weekly data. The stock seem to start a technical rebound at this level. Thus, the stock could find new energy and rise towards the next USD 61.7 resistance.

Therefore, it seems opportune to take a long position on AbbVie and target in a first place the USD 61.7 resistance. Traders should not insist below the USD 55.5 support and a stop-loss order should be placed under this threshold.

Anas Boumedian
© Zonebourse.com 2015
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 32 147 M
EBIT 2018 14 074 M
Net income 2018 10 245 M
Debt 2018 22 341 M
Yield 2018 3,41%
P/E ratio 2018 14,86
P/E ratio 2019 12,78
EV / Sales 2018 5,51x
EV / Sales 2019 5,00x
Capitalization 155 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Duration : Period : Week
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders